The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated•Originally published 20 April 2026•Updated 22 April 2026•

1 min read

PharmaTher Expands Microneedle Platforms Amid U.S. Regulatory Shifts

Key Facts

1PharmaTher is positioning its PatchPrint™ and PharmaPatch™ platforms to benefit from U.S. federal support for psychedelic medicine and therapeutic peptides.

2The company focuses on microneedle patch technologies as a solution for compounding pharmacies, hospitals, and research institutions.

PharmaTher Holdings Ltd. has announced a strategic move to leverage its PatchPrint™ and PharmaPatch™ platforms in response to growing U.S. federal support for psychedelic medicine. The company is positioning its technologies to capitalize on the Executive Order signed on April 18, 2026, aimed at fast-tracking the approval of psychedelic drugs. Specifically, PharmaTher highlighted its KetaVault™ platform and ketamine programs as key strategic assets that stand to benefit from this policy shift. These platforms are designed to serve compounding pharmacies and research institutions seeking efficient drug delivery solutions. By focusing on advanced manufacturing, the company aims to address the increasing demand for innovative therapeutic access. This update follows significant regulatory shifts that create a favorable commercial tailwind for the biotechnology sector and shareholders of PHRRF and PHRM.

about 1 month ago

Version History

Version 1about 1 month ago

What changed: Added the specific date of the Executive Order (April 18, 2026) and identified the KetaVault platform and ketamine programs as primary beneficiaries.